HighTower Advisors LLC Increases Stake in Exelixis, Inc. $EXEL

HighTower Advisors LLC increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 7.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,998 shares of the biotechnology company’s stock after buying an additional 5,879 shares during the period. HighTower Advisors LLC’s holdings in Exelixis were worth $2,990,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Coppell Advisory Solutions LLC purchased a new position in Exelixis in the fourth quarter valued at about $25,000. Hemington Wealth Management grew its stake in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 522 shares during the last quarter. Colonial Trust Co SC grew its stake in Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 765 shares during the last quarter. Bartlett & CO. Wealth Management LLC purchased a new position in Exelixis in the first quarter valued at about $37,000. Finally, Costello Asset Management INC purchased a new position in Exelixis in the first quarter valued at about $39,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of the business’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the completion of the transaction, the director directly owned 358,882 shares of the company’s stock, valued at approximately $15,464,225.38. The trade was a 2.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sue Gail Eckhardt sold 18,838 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $42.74, for a total value of $805,136.12. Following the completion of the transaction, the director directly owned 21,380 shares of the company’s stock, valued at $913,781.20. The trade was a 46.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EXEL. Stephens upgraded Exelixis from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $29.00 to $60.00 in a research note on Tuesday, June 24th. HC Wainwright cut their target price on Exelixis from $53.00 to $46.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Tuesday, July 29th. JMP Securities reissued a “market outperform” rating and issued a $50.00 price target on shares of Exelixis in a report on Tuesday, July 29th. Finally, Bank of America raised their price target on Exelixis from $45.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 5th. Thirteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.06.

Exelixis Stock Down 0.2%

Exelixis stock opened at $38.63 on Friday. Exelixis, Inc. has a 52 week low of $25.12 and a 52 week high of $49.62. The company has a market capitalization of $10.40 billion, a price-to-earnings ratio of 18.57, a price-to-earnings-growth ratio of 0.80 and a beta of 0.29. The stock has a 50-day moving average price of $41.56 and a 200 day moving average price of $39.28.

Exelixis (NASDAQ:EXEL) last released its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same quarter in the previous year, the company posted $0.84 earnings per share. The company’s revenue was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.